


**Global AMR Innovators  
Conference  
22-24 September 2026  
Lisbon, Portugal**

**Preliminary Programme**





# Programme

**Tuesday, 22 September 2026**

---

12:00 – 13:00 Poster mounting

---

13:00 – 14:00 Session Hall

**Welcome and keynote lecture**

Introduction

tba

Keynote lecture 1

Valeria Gigante, Switzerland

Keynote lecture 2

Radu Botgros, Netherlands

---

14:00 – 14:30 Break

---

14:30 – 16:00 Session Hall

**Diagnostic development. When MICs don't make sense: designing development programmes when standard susceptibility testing breaks down**

Amy Mathers (Chair), USA

tba (Chair)

Proving it's not the drug: building the case against standard MIC testing?

Jean Patel, USA

Designing 'non-standard' testing that reflects *in vivo* antimicrobial activity?

Mariana Castanheira, USA

Clinical trials without a standard test: logistics, risk, and reality

Srividya Desai, India

From approval to adoption: diagnostic constraints and market reality

tba

---

16:00 – 16:30 Session Hall

**Lightning talks from poster presenters**

Shampa Das (Chair), UK

Taslimarif Saiyed (Chair), India

tba

---

16:30 – 16:45 Break

---

16:45 – 18:15 Poster area

**Poster session**

tba

---

18:15 – 18:30 Break

---

18:30 – 20:00 Session Hall

**Opening ceremony & reception**

tba

---



# Programme

Wednesday, 23 September 2026

08:30 – 10:00 Session Hall  
**Addressing global gaps: accelerating paediatric antibacterial drug development to meet unmet needs**  
Sumati Nambiar (Chair), USA  
Justin Green (Chair), Switzerland  
What do we need to do to ensure simultaneous adult and adolescent approvals?  
Marcela Ramirez, UK  
What can we do to expedite neonatal product development?  
Tanu Singhal, India  
How do we address the unmet needs of children in LMICs?  
Nina Putri, Indonesia

10:00 – 10:30 Break

10:30 – 10:45 Session Hall  
**CARB-X: A decade in review and a vision for the future**  
Richard Alm (Chair), USA  
CARB-X: A decade in review and a vision for the future  
Kevin Outtersson, USA

10:45 – 12:00 Session Hall  
**Challenges and successes in the clinical development of preventatives against AMR**  
Vega Massignani (Chair), Italy  
Richard Alm (Chair), USA  
tba  
Kate Seib, Australia  
tba  
Veronica Hall, USA

12:00 – 13:00 Break

13:00 – 14:00 Session Hall  
**Decolonisation strategies coming of age: positioning them for success**  
Erin Duffy (Chair), USA  
tba (Chair)  
tba

14:00 – 14:30 Break

14:30 – 15:45 Session Hall  
**From aspiration to application: applying WHO target product profiles to antibiotic R&D**

Valeria Gigante (Chair), Switzerland

tba (Chair)

TPP 1: severe MDR Gram-negative infections (BSI, HABP/VABP) caused by CRAB, CRE, CRPA

Anand Kumar, India

TPP 2: resistant Gram-positive in high-risk patients caused by vancomycin-resistant enterococci (VRE), including vancomycin-resistant *E. faecium* (VREF)

tba

TPP N3: meningitis CA and HCA caused by MDR Gram-negative bacteria and methicillin-resistant *S. aureus*

Seun Makinde, USA

---

15:45 – 16:15

Break

---

16:15 – 16:45

Session Hall

**Lightning talks from poster presenters**

tba

---

16:45 – 17:30

Session Hall

**Keynote lecture**

tba (Chair)

Beta-lactams in jeopardy – the rise of PBP mutations!

Karen Bush

---

17:30 – 17:45

Break

---

17:45 – 19:15

Poster area

**Poster session & reception**

tba

---

# Programme

Thursday, 24 September 2026

08:30 – 10:00	Session Hall <b>Pragmatic session - narrow-spectrum agents: the challenge of bringing phage therapeutics from concept thru late-stage development</b> John Rex (Chair), USA Radu Botgros (Chair), Netherlands Overview of program design: How phages fit into the antimicrobial armamentarium, how phage differ from traditional products, and why reproducibility is the particular focus of this session John Rex, USA PK-PD and dose: animal models, combination strategies, dose ratios Gauri Rao, USA Sustainable manufacturing platform: phage bank development, GMP production, biological variability Frenk Smreckar, Slovenia A regulatory perspective: the platform approach, timing of regulatory guidance, EMA expectations, role of the magistral formula pathway Radu Botgros, Netherlands
10:00 – 10:30	Break
10:30 – 12:00	Session Hall <b>Issues in clinical development</b> David Paterson (Chair), Singapore Florian Maurer (Chair), Switzerland Lessons from a successful superiority trial tba Do we need Phase II clinical trials? Clare Nasmyth-Miller, UK Single arm trials: is LPAD still an option? Sumathi Nambiar, USA Panel discussion All speakers
12:00 – 13:00	Break
13:00 – 14:00	Session Hall <b>Funding for clinical development</b> David Paterson (Chair), Singapore Richard Alm (Chair), USA Sources of non-dilutive funding Richard Alm, USA AMR Action Fund: who should apply and when?

Henry Skinner, USA

Raising public funds via an IPO

Marc Gitzinger, Switzerland

Is fund-raising for antibiotic trials any easier in a large company?

tba

---

14:00 – 14:30 Break

---

14:30 – 15:45 Session Hall

**When innovation is not enough: access challenges in antibiotics**

Elena Breidenstein (Chair), UK

Regina Osih (Chair), South Africa

Setting the scene on global access to existing and new antibiotics

Yann Ferrisse, Switzerland

Access to existing antibiotics

tba

Access to reserve antibiotics

tba

Panel discussion

All speakers

---

15:45 – 16:15 Break

---

16:15 – 17:15 Session Hall

**Global insecurity and AMR: adapting narratives to shifting geopolitics**

Frédéric Peyrane (Chair), France

Jomana F. Musmar (Chair), USA

AMR conflict progression and One Health implications in policy

Jomana F. Musmar (Chair), USA

Force multipliers of AMR and impact on treatment decisions

Souha Kanj, Lebanon

Investment, development, access, & policies in diverse settings

Manica Balasegaram, Switzerland

National resilience & response impact on federal decisions

Monisha Ashok, USA

---

17:15 – 17:45 Session Hall

**Closing remarks**

tba

---

